Climb Bio, Inc. Files 8-K on Officer/Director Changes
Ticker: CLYM · Form: 8-K · Filed: Oct 1, 2025 · CIK: 1768446
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election, compensation
TL;DR
Climb Bio (CLIM) filed an 8-K detailing leadership changes and executive pay. Watch for updates.
AI Summary
Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K on October 1, 2025, reporting on events as of September 30, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and details compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in Climb Bio's leadership and executive compensation structure, which could impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with details on compensatory arrangements, can signal internal shifts that may affect company strategy and performance.
Key Players & Entities
- Climb Bio, Inc. (company) — Registrant
- Eliem Therapeutics, Inc. (company) — Former company name
- September 30, 2025 (date) — Date of earliest event reported
- October 1, 2025 (date) — Date of report
FAQ
Who has departed from Climb Bio, Inc.'s board or officer positions?
The filing indicates the departure of directors or certain officers, but specific names are not detailed in the provided text.
Were new directors or officers appointed?
Yes, the filing reports on the election of directors and the appointment of certain officers.
What information is provided regarding executive compensation?
The filing covers compensatory arrangements of certain officers.
What is the former name of Climb Bio, Inc.?
The former name of Climb Bio, Inc. was Eliem Therapeutics, Inc., with a name change date of February 19, 2019.
What are the key items reported in this 8-K filing?
The key items reported are the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and financial statements and exhibits.
Filing Stats: 1,751 words · 7 min read · ~6 pages · Grade level 11.1 · Accepted 2025-10-01 17:23:33
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CLYM The Nasdaq Stock Mar
- $510,000 — tschuller will be paid a base salary of $510,000 per year. Dr. Altschuller will also be
Filing Documents
- d33819d8k.htm (8-K) — 36KB
- d33819dex101.htm (EX-10.1) — 59KB
- g33819g1002000749355.jpg (GRAPHIC) — 2KB
- 0001193125-25-227025.txt ( ) — 234KB
- clym-20250930.xsd (EX-101.SCH) — 3KB
- clym-20250930_lab.xml (EX-101.LAB) — 18KB
- clym-20250930_pre.xml (EX-101.PRE) — 11KB
- d33819d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Offer Letter, dated September 30, 2025, between Climb Bio, Inc. and Susan Altschuller, Ph.D., MBA 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Climb Bio, Inc. Date: October 1, 2025 By: /s/ Aoife Brennan Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer